“Adding a personalized mRNA-based cancer vaccine to immunotherapy after surgery for high-risk melanoma reduced the risk of recurrence or death by 42%, according to results from the phase III INTerpath-001 trial presented at the European Society for Medical Oncology (ESMO) Congress 2026 (Abstract LBA1). The vaccine, intismeran autogene, was given alongside pembrolizumab and compared with pembrolizumab alone.”

From The ASCO Post.